Beijing, China – 11 Sep 2026 – China’s National Medical Products Administration (NMPA) has approved two registration applications for pathogen metagenomic next‑generation sequencing (mNGS) test reagents, marking the first batch of such products cleared for market in China. The two kits — developed by Guangzhou Weiyuan Medical Devices Co., Ltd. for respiratory infections and Tianjin Jinshi Medical Technology Co., Ltd. for bloodstream infections — respectively represent the world’s first mNGS‑based respiratory pathogen test reagent and China’s first mNGS reagent for bloodstream infection, signaling that China has taken a global lead in the clinical translation of metagenomic testing technology.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | NMPA (China); reviewed by the Center for Medical Device Evaluation (CMDE) |
| Approval Type | Medical device registration – first batch of pathogen mNGS in‑vitro diagnostic reagents |
| Products | Weiyuan Respiratory Pathogen Nucleic Acid Test Kit (combinatorial probe‑anchored polymerase sequencing); Jinshi Bloodstream Infection Pathogen Nucleic Acid Test Kit (reversible‑terminator sequencing) |
| Use | Auxiliary diagnosis of critical, refractory, and special infection cases |
| Approval Date | Announced recently; exact date Not disclosed |
| Review Duration | Approximately four years from application receipt to approval |
| Next Steps | Companion laboratory guidelines in force; further mNGS products in development and review – additional guidance documents in preparation |
Product Profile & Mechanism of Action
- Modality: Culture‑independent pathogen metagenomic testing — broad‑spectrum, high‑throughput sequencing of all nucleic acids in a sample, followed by bioinformatic analysis integrated with clinical information to identify causative pathogens; in theory capable of detecting every pathogen covered by the reference database, including rare fungi and intracellular bacteria.
- Respiratory Product (Weiyuan): For auxiliary diagnosis of suspected lower respiratory tract infection in critically ill patients, immunocompromised patients, and diagnostically challenging cases – the world’s first mNGS respiratory pathogen reagent.
- Bloodstream Product (Jinshi): For patients with suspected bloodstream infection in whom conventional methods such as blood culture fail to confirm the pathogen, and for severe/critical bloodstream infections including sepsis – China’s first mNGS reagent in this setting.
- Single‑Sample Multiplexing: One specimen run delivers multi‑category pathogen information simultaneously, addressing the “race against time” in critical infection care.
- Standardized Quality Control: Product‑level approval establishes defined operating norms and quality metrics across the entire workflow – sample collection, nucleic acid extraction, library preparation, sequencing, and bioinformatic analysis – sharply improving reliability and reproducibility versus hospital self‑developed (LDT) testing.
- Safety Guardrails: The CMDE coordinated with the National Center for Clinical Laboratories (NCCL) to produce the “Guideline for Standardized Clinical Laboratory Application of Metagenomic High‑Throughput Sequencing Technology (2026 Edition)”, setting laboratory access thresholds, environmental conditions, personnel qualifications, and result‑interpretation capabilities before market launch.
Clinical Evidence – Multi‑Center Registration Trials
| Endpoint | Result | Context |
|---|---|---|
| Pathogen Detection Rate (validated panel, clinically confirmed infection cases) | >95% for both products | Among cases clinically diagnosed as positive with identified pathogen infection |
| Incremental Detection of Hard‑to‑Identify Pathogens | 28.53% (respiratory kit); 30% (bloodstream kit) | Share of detected pathogens that conventional methods struggle to identify |
| Validation Panel | ~40 representative pathogens selected through nearly ten expert consensus meetings | Covered trial design questions: pathogen selection, sample size estimation, statistical analysis |
| Trial Duration | Two years | Large‑scale studies at leading sites including Peking Union Medical College Hospital and the First Affiliated Hospital of Guangzhou Medical University |
| Reproducibility Study | Samples from 3 clinical trial institutions | Non‑routine requirement imposed by reviewers to verify robustness against background microbial interference across laboratory environments, seasons, and operating conditions |
The reviewers’ added cross‑environment reproducibility requirement — described by CMDE officials as atypical for IVD clinical evaluation but essential with no marketed comparators — underpins confidence that the products can withstand nationwide deployment across hospital tiers.
Market Impact & Outlook
- Clinical Need: Lower respiratory tract infection alone accounts for roughly 2 million critical and diagnostically difficult cases per year in China; these patients progress rapidly, and identifying the pathogen within the golden window is directly life‑or‑death — a need traditional narrow‑coverage or slow culture/PCR methods often fail to meet.
- Access Expansion: Unlike in‑house LDT reagents restricted to a single hospital, NMPA‑approved kits can serve all qualified medical institutions, including via regional testing centers and referral testing — potentially giving county‑level hospitals in remote areas the same test quality as top‑tier centers, once standardized sample collection, cold‑chain transport, and remote reporting are in place.
- Regulatory Precedent: With no global review framework to reference, the CMDE built from scratch a complete evaluation system spanning performance assessment, clinical validation, bioinformatic analysis, and environmental quality control over four years — experience now converting into reusable regulatory‑science outputs, with series guidance principles underway jointly with the National Institutes for Food and Drug Control and NCCL.
- Supply‑Chain Upgrade: Review requirements extended upstream: traceable QC standards for primers, enzymes, adapters, and kit consumables, plus periodic supplier audits — driving quality‑control improvements across the entire mNGS industry chain, from raw materials to cold‑chain logistics.
- Pipeline Momentum: Multiple additional mNGS products are progressing through development and review, positioning China as the first major market to move pathogen metagenomics from exploratory hospital use into standardized, regulated IVD products.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the clinical adoption, reimbursement coverage, subsequent guidance documents, and pipeline approvals related to pathogen mNGS test reagents in China. Actual outcomes may differ due to laboratory qualification requirements, implementation variability across institutions, regulatory timelines for additional products, and competitive dynamics.-China Health Reform Pulse
Policy Source: https://www.cmde.org.cn/xwdt/zxyw/20260910085307102.html